Biosimilars In EU Seeing Reduced Clinical Data Requirements
This article was originally published in PharmAsia News
After a 'slightly conservative approach' at the beginning, 'we are now getting to the meat of what we can do with biosimilars,' the European Medicine Association's Head of Quality Peter Richardson says.
You may also be interested in...
Following a consultation last year, Medsafe has set new fee levels that take account of both cost-recovery principles and a 4.2% increase in the consumer price index.
The monkeypox cases reported this month are evidence of chains of transmission of the virus, according to the European Centre for Disease Prevention and Control, which says that vaccination of high-risk close contacts should be considered after a benefit-risk assessment.
Coronavirus Notebook: WHO Says Extra Vaccine Boosters Confer Some Limited Benefits, Emergex & Zosano Link Up On T Cell Vaccine Patch
International regulators have issued an updated statement on the benefits and safety of COVID-19 vaccines for use by health professionals, while the UK BioIndustry Association has welcomed a MAb licensing deal between AstraZeneca and UK-based biotech firm RQ Bio.